Efficacy and safety of adalimumab in the treatment of Crohn´s disease in children.

@article{NavasLpez2013EfficacyAS,
  title={Efficacy and safety of adalimumab in the treatment of Crohn´s disease in children.},
  author={V. Navas-L{\'o}pez and J. Blasco-Alonso and F. Gir{\'o}n-Fern{\'a}ndez-Crehuet and Mar{\'i}a Juliana Serrano-Nieto and C. Sierra-Salinas},
  journal={Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva},
  year={2013},
  volume={105 10},
  pages={
          579-84
        }
}
OBJECTIVES to describe the efficacy and safety of adalimumab (ADA) in inducing clinical remission and reducing inflammation of intestinal mucosa in children with Crohn´s disease (CD). METHODS we carried out a descriptive, observational study with all patients diagnosed with CD and treated with ADA between January 2007 and March 2013. Disease activity was determined using the Pediatric Crohn´s Disease Activity Index (PCDAI), and the degree of mucosa inflammation by fecal calprotectin (FC… Expand
Adalimumab and Infliximab in Crohn’s disease - real life data from a national retrospective cohort study
Biological Therapy in Pediatric Inflammatory Bowel Disease: A Systematic Review
Biological Therapy in Pediatric Age.
...
1
2
3
...

References

SHOWING 1-10 OF 41 REFERENCES
Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in Pediatric Crohn’s Disease
Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children.
Safety and Efficacy of Adalimumab in Pediatric Patients With Crohn Disease
Adalimumab Treatment in Children with Refractory Crohn’s Disease
Efficacy of Adalimumab in Moderate-to-Severe Pediatric Crohn's Disease
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
Short‐term response to adalimumab in childhood inflammatory bowel disease
Long-term efficacy of adalimumab in paediatric Crohn's disease patients naïve to other anti-TNF therapies.
Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn’s disease in children: REACH open-label extension
...
1
2
3
4
5
...